THRX's logo.
Ticker Symbol: THRX

Theseus Pharmaceuticals Inc

$17.28 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001745020

Company Profile

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: theseusrx.com
CEO: N/A
Tags: N/A

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $2.50
Change: -$0.07 ( -2.72%)
Days Range: $2.40 - $2.57
Beta: 1.80
52wk. High: $14.77
52wk. Low: $2.27
Ytd. Change -51.12%
50 Day Moving Average: $2.71
200 Day Moving Average: $6.40
Shares Outstanding: 43603369

Valuation

Market Cap: 10.9B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A